Literature DB >> 12384378

Pharmacokinetics and pharmacodynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a granulocyte-rich exudate.

Andrej Trampuz1, Gerd Laifer, Markus Wenk, Zarko Rajacic, Werner Zimmerli.   

Abstract

The pharmacokinetics of gatifloxacin were assessed in serum and in skin blister fluid (SBF), as was the pharmacodynamic activity in SBF. Five hours after a single dose of gatifloxacin, SBF killed 2.5 logs of Streptococcus pneumoniae and 1.5 log of Staphylococcus aureus during a 2-h incubation ex vivo.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12384378      PMCID： PMC128756          DOI： 10.1128/AAC.46.11.3630-3633.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  In-vitro activity of gatifloxacin, a novel fluoroquinolone, compared with that of ciprofloxacin against Legionella spp.

Authors:  S L Pendland; K J Losnedahl; C A Schriever
Journal:  J Antimicrob Chemother       Date:  1999-08       Impact factor: 5.790

2.  Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.

Authors:  A Trampuz; M Wenk; Z Rajacic; W Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria.

Authors:  R Schaumann; G Ackermann; B Pless; M C Claros; A C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

4.  A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose.

Authors:  R Wise; J M Andrews; J P Ashby; J Marshall
Journal:  J Antimicrob Chemother       Date:  1999-11       Impact factor: 5.790

5.  A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men.

Authors:  D A Gajjar; F P LaCreta; H D Uderman; G D Kollia; G Duncan; M J Birkhofer; D M Grasela
Journal:  Pharmacotherapy       Date:  2000-06       Impact factor: 4.705

6.  In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors:  P M Roblin; M R Hammerschlag
Journal:  J Antimicrob Chemother       Date:  1999-10       Impact factor: 5.790

Review 7.  Clinical pharmacology of gatifloxacin, a new fluoroquinolone.

Authors:  D M Grasela
Journal:  Clin Infect Dis       Date:  2000-08       Impact factor: 9.079

8.  Antimycobacterial activities of novel levofloxacin analogues.

Authors:  K Kawakami; K Namba; M Tanaka; N Matsuhashi; K Sato; M Takemura
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

9.  The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin.

Authors:  K Nye; Y G Shi; J M Andrews; J P Ashby; R Wise
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

10.  Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers.

Authors:  C K Naber; M Steghafner; M Kinzig-Schippers; C Sauber; F Sörgel; H J Stahlberg; K G Naber
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191
View more
  4 in total

Review 1.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials.

Authors:  Die Cheng; Wei-Ren Xu; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

3.  Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum.

Authors:  Gary E Stein; Sharon Schooley; Kerin L Tyrrell; Diane M Citron; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

4.  Skin and skin structure infections: treatment with newer generation fluoroquinolones.

Authors:  Philip Giordano; Kurt Weber; Gail Gesin; Jason Kubert
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.